Why did CureVac terminate the development of COVID-19 mRNA vaccine?
- Aspirin: Study Finds Greater Benefits for These Colorectal Cancer Patients
- Cancer Can Occur Without Genetic Mutations?
- Statins Lower Blood Lipids: How Long is a Course?
- Warning: Smartwatch Blood Sugar Measurement Deemed Dangerous
- Mifepristone: A Safe and Effective Abortion Option Amidst Controversy
- Asbestos Detected in Buildings Damaged in Ukraine: Analyzed by Japanese Company
Why did CureVac terminate the development of COVID-19 mRNA vaccine?
- Red Yeast Rice Scare Grips Japan: Over 114 Hospitalized and 5 Deaths
- Long COVID Brain Fog: Blood-Brain Barrier Damage and Persistent Inflammation
- FDA has mandated a top-level black box warning for all marketed CAR-T therapies
- Can people with high blood pressure eat peanuts?
- What is the difference between dopamine and dobutamine?
- How long can the patient live after heart stent surgery?
Why did CureVac terminate the development of COVID-19 mRNA vaccine?
Another pharmaceutical company gave up its first-generation COVID-19 vaccine research and development! Bayer, CureVac terminate the COVID-19 vaccine
CureVac announced the abandonment of the COVID-19 mRNA vaccine research and development, and the focus of subsequent development shifts to the second-generation vaccine.
On October 12, CureVac announced the withdrawal of its first-generation COVID-19 vaccine candidate CVnCoV from the EMA approval process. This decision also means that the company’s previous 405 million dose vaccine pre-purchase agreement with the European Commission will be terminated.
Prior to August, CureVac and GlaxoSmithKline announced preclinical data on the immune response. The data showed that compared with the first-generation candidate vaccine CVnCoV, the second-generation vaccine candidate CV2CoV better activated the innate and adaptive immune response. , So as to start the immune response faster, and have a higher antibody titer and stronger memory B cell and T cell activation effect.
The company expects to advance the second-generation mRNA vaccine to late-stage clinical practice in the first half of 2022, and seek regulatory approval in the same year.
On September 28, the French pharmaceutical giant Sanofi announced that it would stop the third phase of the messenger ribonucleic acid COVID-19 vaccine. The reason is that the vaccine has missed the best time to market. The company said that it will continue to promote the recombinant protein COVID-19 vaccine. Research and development work.
Bayer AG recently stated that it has terminated a vaccine production partnership under which Bayer will help CureVac produce its COVID-19 vaccine.
Why did CureVac terminate the development of COVID-19 mRNA vaccine?
(source:internet, reference only)
Disclaimer of medicaltrend.org
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.
